MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03299855

Acronym

MOCA-2

Enrollment

104

Registered

2017-10-03

Start date

2017-10-13

Completion date

2023-10-13

Last updated

2023-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

oncogeriatric, MMS, MoCA

Brief summary

This study concerns elderly patients with cancer with onco-geriatric assessment. This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Interventions

OTHERPassation of neuropsychological test

Passation of MoCA and MMS tests associated with neuropsychological test

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

SINGLE (Subject)

Intervention model description

Passation of MMS and MoCA tests associated to passation of neuropsychological test

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient aged over 70 years * Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study. * Patient candidate for oncogeriatric assessment * Patient agree to participate in the study * Using the French language

Exclusion criteria

* Primary central nervous system or cerebral metastasis * Evolutionary psychiatric pathology known (e.g. schizophrenia) * Severe Visual and / or Auditory Impairment * Patients unable to respond to cognitive tests * Patient (s) deprived of liberty, under guardianship or curatorship * Refusal of participation

Design outcomes

Primary

Measure	Time frame	Description
Evaluate the sensitivity of MoCA test	Up 2 months after inclusion, before initiation of treatment	MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026